Expert faculty for this 30-minute webinar will include a gynecologic oncologist and a nurse. This webinar will provide an overview of the latest data in PARP inhibitor therapy for the treatment of ovarian cancer in patients with different biomarker profiles and at different stages of the disease. Recent clinical data and rationale for PARP inhibitor use in the first-line maintenance setting will be discussed. Faculty will share unique toxicity profiles among the different PARP inhibitors and best practices in monitoring, preventing, and treating adverse events that may arise with therapy.
Center for Gynecologic Oncology
Massachusetts General Hospital
Boston, MA
Professor and Vice Chair of Women’s Health Research
Department of Obstetrics and Gynecology, David Geffen School of Medicine at UCLA
Director, Cancer Population Genetics
UCLA-Jonsson Comprehensive Cancer Center, Los Angeles, CA
Expert faculty for this 30-minute webinar will include a pathologist and a gynecologic oncologist. Faculty will summarize the latest guidelines on genes that should be tested in ovarian cancer and the appropriate identification of patients who should receive testing.
Professor and Vice Chair of Women’s Health Research
Department of Obstetrics and Gynecology, David Geffen School of Medicine at UCLA
Director, Cancer Population Genetics
UCLA-Jonsson Comprehensive Cancer Center, Los Angeles, CA
Professor of Clinical Pathology
Department of Pathology, USC Keck School of Medicine
University of Southern California, Los Angeles, CA
Expert faculty for this 30-minute webinar will include perspectives from a patient, a medical oncologist, and an oncology nurse.
Professor and Vice Chair of Women’s Health Research
Department of Obstetrics and Gynecology, David Geffen School of Medicine at UCLA
Director, Cancer Population Genetics
UCLA-Jonsson Comprehensive Cancer Center, Los Angeles, CA
GYN OncologyAdvanced Practice Nurse
UCLA Health, Los Angeles, CA
Bladder cancer thought leaders Drs. Sam Chang and Shilpa Gupta review the rapidly evolving bladder cancer treatment landscape across the full continuum of care, from emerging data in NMIBC, to novel neoadjuvant and adjuvant regimens in MIBC, to robust paradigmatic changes in locally advanced and mUC, both in the front-line setting and in subsequent lines of therapy.
Professor, Department of Urology
Patricia and Rodes Hart Professor of Urologic Surgery
Chief Surgical Officer
Division of Urologic Oncology, Vanderbilt Ingram Cancer Center, Nashville, TN
Director of the Genitourinary Medical Oncology
Cleveland Clinic
Co-Leader of the Genitourinary Oncology Program
Taussig Cancer Institute, Cleveland, OH
All clinicians managing patients with non-dialysis-dependent chronic kidney disease or heart failure must be aware of the deleterious impacts of concomitant anemia and the established, emerging, and practice-changing role of intravenous (IV) iron therapies.
President, Baylor Scott and White Research Institute, Dallas, TX
Distinguished Professor of Medicine
University of Mississippi, Jackson, MS
Director, Division of Nephrology
Professor of Medicine
University of Maryland Medical System
Baltimore, MD
Strategically designed to foster an understanding of both the disease state complexity and far-reaching disparity intrinsic to endometrial cancer, this educational session will begin with an appraisal of the utility and importance of biomarker testing in advanced endometrial cancer, and the latest data related to immune checkpoint inhibitor treatments.
